spacer
home > epc > spring 2009 > the value proposition
PUBLICATIONS
European Pharmaceutical Contractor

The Value Proposition

Pharmaceutical and biotech companies are increasingly interested in the use of ‘adaptive’ clinical trials to improve the process of drug development. By an ‘adaptive trial’, we mean a trial that is designed from the outset to review key response data as we collect it, and carry out certain pre-specified adaptations in the light of what we learn.

In large confirmatory trials, regulatory concerns will limit adaptations that can be considered to actions such as stopping the trial early, performing a sample size re-assessment or dropping a treatment arm. In early phase trials, frequent adaptation and a wider scope for adaptation are permitted, for instance: frequent optimisation of the probabilities of adaptation to the different treatment arms; more frequent interims to choose to drop or add treatment arms or to stop the trial; modification of inclusion and exclusion criteria to drop patient subpopulations from the study or restrict the study to a sub-population.

 


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Tom Parke joined Tessella in 1996, and has worked on supporting adaptive clinical trials since 1998. He managed the development of the system that allowed Pfizer to run their groundbreaking ASTIN trial, and has worked on numerous further dose response adaptive trials. He has overseen the development of algorithms, simulation tools and systems to support adaptive trials, as well as integrating adaptive algorithms with existing central randomisation and electronic data capture systems. Whilst currently working on his twelfth dose-response adaptive trial, Tom is consulting with a number of international pharmaceutical companies, helping them to define the software systems they require to run adaptive clinical trials.

spacer
Tom Parke
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Wrap Around Label - A Lot of Content in a Small Space

Faubel & Co. Nachfolger GmbH

One of the world’s largest contract research organizations for the planning and conducting of clinical trials was faced with the challenge of accommodating many different national languages on an inhaler. The inhaler was then to be distributed in 47 countries. Due to the impressive quality and reliable collaboration, the organization commissioned Faubel with finding the optimal labeling solution for the inhaler.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement